NCT06738251招募中3 期
A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A2102 for Injection Versus Investigator-selected Therapy in Locally Advanced or Metastatic Urothelial Carcinoma Previously Treated With Platinum-Containing Chemotherapy and PD-(L)1 Inhibitors and With or Without ADC
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 402
- 试验地点
- 1
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
To evaluate the efficacy and safety of SHR-A2102 for injection versus Investigator-selected Therapy in patients with Locally advanced or Metastatic Urothelial Carcinoma who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in this clinical study, understand the study procedures and be able to sign the informed consent form in writing.
- •18 to 80 years old (including boundary value), gender is not limited.
- •ECOG performance status score of 0 or
- •Estimated survival ≥ 3 months.
- •Pathologically confirmed urothelial carcinoma confirmed by imaging or other methods as locally advanced unresectable or metastatic disease.
- •Patients with locally advanced or metastatic disease who have previously received both a platinum-based chemotherapy regimen and a PD-(L)1 inhibitor; patients who received platinum-based chemotherapy and/or a PD-(L)1 inhibitor as neoadjuvant or adjuvant therapy and experienced recurrence or progression during treatment or within 6 months after completing treatment will be considered to have received these therapies in the locally advanced/metastatic setting.
- •Imaging-confirmed disease progression during or after treatment with the most recent regimen.
- •Able to provide preserved or fresh tumor tissue.
- •Must be present with at least one measurable lesion according to RECIST v1.1 criteria.
- •Good level of organ function.
- •Male subjects whose partners are women of childbearing potential and female subjects of childbearing potential must use highly effective contraception from the time of signing the informed consent form until 8 months after the last dose of the trial drug.
排除标准
- •Planned to receive any other anti-tumor therapy during this trial.
- •Receipt of other unmarketed clinical trial drugs or treatments within 4 weeks prior to randomization.
- •Received systemic anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks prior to randomization, and palliative radiotherapy or local therapy within 2 weeks prior to the first use of the investigational drug.
- •Prior receipt of antibody-drug conjugates containing topoisomerase I inhibitors in the composition.
- •For locally advanced or metastatic disease: patients who have previously received more than three lines of systemic therapy in this setting.For neoadjuvant or adjuvant therapy: if the disease recurs or progresses during treatment or within 6 months after its completion, the patient is considered to have received first-line systemic therapy for locally advanced or metastatic disease.
- •Prior treatment with more than 1 antibody-drug conjugate.
- •Major surgery other than diagnosis or biopsy within 4 weeks prior to randomization that requires elective surgery during the trial.
- •Received systemic glucocorticoids (prednisone > 10 mg/day or equivalent dose) or other immunosuppressants within 14 days prior to the first use of investigational drug or randomization for immunosuppressive purposes.
- •Adverse events from prior antineoplastic therapy did not recover to Grade ≤1 according to NCI-CTCAE v5.
- •Inadequately treated central nervous system (CNS) metastases, or the presence of uncontrolled or symptomatic active central nervous system metastases. CNS metastases that have been adequately treated and whose neurological symptoms are able to return to baseline at least 4 weeks prior to randomization (with the exception of residual signs or symptoms associated with CNS treatment) may be enrolled in the study.
- •Subject has a serous effusion with clinical symptoms or requiring puncture and drainage.
- •Any malignancy diagnosed within 5 years prior to randomization (calculated from the date of the last anti-tumor treatment), except:Localized, low-risk prostate cancer.Papillary thyroid carcinoma, basal-cell carcinoma, or squamous-cell carcinoma of the skin that has been adequately treated and shows no evidence of disease.Other carcinomas in situ that have been adequately treated and show no evidence of disease recurrence.
- •History of interstitial pneumonitis/interstitial lung disease or non-infectious pneumonitis (e.g., radiation pneumonitis) that required systemic corticosteroid therapy.Current evidence, in the investigator's judgment, of uncontrolled interstitial pneumonitis/interstitial lung disease, non-infectious pneumonitis, or any other active pneumonitis.
- •Severe infections requiring intravenous antibiotics, antivirals, or antifungals for control.
- •Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •Has a history of immunodeficiency or organ transplantation.
- •Any serious arterial or venous thrombotic event within 6 months before randomization.
- •Those who have had significant clinically significant bleeding symptoms within 3 months before the first study drug.
- •Glycosylated hemoglobin (HbA1c) ≥8%.
- •Have severe cardiovascular and cerebrovascular diseases.
- •Allergic reaction to any component of this study treatment.
- •Female subjects who are pregnant or plan to become pregnant during the study.
- •According to the judgment of the investigator, there are concomitant diseases (such as thyroid disease and mental illness, etc.) or any other conditions that seriously endanger the safety of the patient, or affect the patient's completion of this study.
- •Prior treatment for urothelial carcinoma with all chemotherapy agents included in the control-arm regimen.
研究组 & 干预措施
SHR-A2102 group
Experimental
干预措施: SHR-A2102 for Injection (Drug)
Investigator-selected therapy group
Active Comparator
干预措施: Docetaxel Injection (Drug)
Investigator-selected therapy group
Active Comparator
干预措施: Paclitaxel Injection (Drug)
Investigator-selected therapy group
Active Comparator
干预措施: Gemcitabine Hydrochloride for Injection (Drug)
Investigator-selected therapy group
Active Comparator
干预措施: Pemetrexed Disodium for Injection (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: Up to approximately 1.5 years.
Overall Survival (OS)
时间窗: Up to approximately 1.5 years and 2 years.
次要结局
- Objective Response Rate (ORR)(Up to approximately 1.5 years and 2 years.)
- Disease Control Rate (DCR)(Up to approximately 1.5 years and 2 years.)
- Duration of Response (DoR)(Up to approximately 1.5 years and 2 years.)
- Serum concentrations of SHR-A2102(Up to approximately 2 years.)
- Serum concentrations of SHR-A2102 toxin(Up to approximately 2 years.)
- Anti-SHR-A2102 antibody (ADA)(Up to approximately 2 years.)
- Anti-SHR-A2102 neutralizing antibody (NAb)(Up to approximately 2 years.)
- Incidence and severity of adverse event (AE)(Up to approximately 2 years.)
- Incidence and severity of serious adverse event (SAE)(Up to approximately 2 years.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsAdvanced Solid TumorsNCT06417554Shanghai Hengrui Pharmaceutical Co., Ltd.80
招募中
1 期
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial CarcinomaAdvanced Urothelial CarcinomaNCT06639347Shanghai Hengrui Pharmaceutical Co., Ltd.90
招募中
1 期
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT06589778Shanghai Hengrui Pharmaceutical Co., Ltd.124
招募中
2 期
A Study of SHR-A1811 in Subjects With Gynaecologic OncologyGynaecological MalignanciesNCT05896020Jiangsu HengRui Medicine Co., Ltd.225
招募中
2 期
A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyAdvanced Gynecological MalignancyNCT06654440Shanghai Hengrui Pharmaceutical Co., Ltd.100